NCT01238042

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

A Pilot Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patient's with High Grade Dysplasia, Carcinoma in situ or Early Adenocarcinoma in Barrett's Esophagus are injected with HPPH and one day later are endoscopically treated with light from a laser.

Conditions

• Barrett's Esophagus
• CIS
• HGD

Interventions

Type	Name	Description
DRUG	HPPH	3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm

Timeline

• Start date: 2003-03-01
• Primary completion: 2004-10-01
• Completion: 2014-11-01
• First posted: 2010-11-10
• Last updated: 2014-12-02

Locations

1 site across 1 country: United States